Clinical use of sirolimus-eluting stents.
Drug-eluting stents, or intracoronary stents that combine the local delivery of antirestenotic pharmacologic therapies while maintaining the mechanical advantage of bare metal stents over balloon angioplasty alone, are a highly complex technology that have profoundly affected the practice of percutaneous coronary intervention over the last 5 years. These devices were designed specifically to treat the neointimal hyperplasia occurring after conventional bare metal stent placement, and have been remarkably successful in this regard. However, recent concerns have been raised regarding the long-term safety of these devices, particularly when used outside of the specific patient and lesion subsets studied in the pivotal randomized trials that led to device approval by regulatory bodies within the United States and abroad. This review aims to present a brief description of the sirolimus-eluting stent device platform and its mechanism of action, followed by an overview of current data regarding efficacy and safety regarding the clinical use of sirolimus-eluting stent technology.
Kirtane
Ajay J
AJ
Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY 10032, USA. ak189@columbia.edu
Leon
Martin B
MB
D000818:Animals; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods; D054855:Drug-Eluting Stents; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000295:instrumentation / Q000379:methods; D016896:Treatment Outcome
D020123:Sirolimus